FMP
NASDAQ
129.32 USD
-0.91 (-0.704%)
Mr. Douglas S. Ingram Esq.
Healthcare
Biotechnology
https://www.sarepta.com
NASDAQ
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping tech...
0000873303
US8036071004
803607100
215 First Street
617 274 4000
US
1,314
Jun 4, 1997
0000873303
NASDAQ
Biotechnology
Healthcare
803607100
US8036071004
US
129.32
0.93
1.08M
12.14B
-
55.25-159.89
137.69
-
-
-
-
-22.34
-
https://www.sarepta.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.